

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Mackle, D;Bellomo, R;Bailey, M;Beasley, R;Deane, A;Eastwood, G;Finfer, S;Freebairn, R;King, V;Linke, N;Litton, E;McArthur, C;McGuinness, S;Panwar, R;Young, P

Title:

Conservative oxygen therapy during mechanical ventilation in the ICU

Date:

2020-03-12

Citation:

Mackle, D., Bellomo, R., Bailey, M., Beasley, R., Deane, A., Eastwood, G., Finfer, S., Freebairn, R., King, V., Linke, N., Litton, E., McArthur, C., McGuinness, S., Panwar, R. & Young, P. (2020). Conservative oxygen therapy during mechanical ventilation in the ICU. *New England Journal of Medicine*, 382 (11), pp.989-998. <https://doi.org/10.1056/NEJMoa1903297>.

Persistent Link:

<https://hdl.handle.net/11343/257853>

Conservative Oxygen Therapy during Mechanical Ventilation in the ICU

The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group*

ABSTRACT

BACKGROUND

Patients who are undergoing mechanical ventilation in the intensive care unit (ICU) often receive a high fraction of inspired oxygen (F_{iO_2}) and have a high arterial oxygen tension. The conservative use of oxygen may reduce oxygen exposure, diminish lung and systemic oxidative injury, and thereby increase the number of ventilator-free days (days alive and free from mechanical ventilation).

METHODS

We randomly assigned 1000 adult patients who were anticipated to require mechanical ventilation beyond the day after recruitment in the ICU to receive conservative or usual oxygen therapy. In the two groups, the default lower limit for oxygen saturation as measured by pulse oximetry (SpO_2) was 90%. In the conservative-oxygen group, the upper limit of the SpO_2 alarm was set to sound when the level reached 97%, and the F_{iO_2} was decreased to 0.21 if the SpO_2 was above the acceptable lower limit. In the usual-oxygen group, there were no specific measures limiting the F_{iO_2} or the SpO_2 . The primary outcome was the number of ventilator-free days from randomization until day 28.

RESULTS

The number of ventilator-free days did not differ significantly between the conservative-oxygen group and the usual-oxygen group, with a median duration of 21.3 days (interquartile range, 0 to 26.3) and 22.1 days (interquartile range, 0 to 26.2), respectively, for an absolute difference of -0.3 days (95% confidence interval [CI], -2.1 to 1.6 ; $P=0.80$). The conservative-oxygen group spent more time in the ICU with an F_{iO_2} of 0.21 than the usual-oxygen group, with a median duration of 29 hours (interquartile range, 5 to 78) and 1 hour (interquartile range, 0 to 17), respectively (absolute difference, 28 hours; 95% CI, 22 to 34); the conservative-oxygen group spent less time with an SpO_2 exceeding 96%, with a duration of 27 hours (interquartile range, 11 to 63.5) and 49 hours (interquartile range, 22 to 112), respectively (absolute difference, 22 hours; 95% CI, 14 to 30). At 180 days, mortality was 35.7% in the conservative-oxygen group and 34.5% in the usual-oxygen group, for an unadjusted odds ratio of 1.05 (95% CI, 0.81 to 1.37).

CONCLUSIONS

In adults undergoing mechanical ventilation in the ICU, the use of conservative oxygen therapy, as compared with usual oxygen therapy, did not significantly affect the number of ventilator-free days. (Funded by the New Zealand Health Research Council; ICU-ROX Australian and New Zealand Clinical Trials Registry number, ACTRN12615000957594.)

The members of the writing committee (Diane Mackle, M.N., Rinaldo Bellomo, M.D., Michael Bailey, Ph.D., Richard Beasley, M.D., D. Sc., Adam Deane, M.D., Ph.D., Glenn Eastwood, R.N., Ph.D., Simon Finfer, M.D., Ross Freebairn, M.D., Victoria King, R.N., Natalie Linke, R.N., Edward Litton, M.D., Ph.D., Colin McArthur, M.D., Shay McGuinness, M.D., Rakshit Panwar, M.D., and Paul Young, M.D., Ph.D.) assume responsibility for the overall content and integrity of this article.

The affiliations of the members of the writing committee are listed in the Appendix. Address reprint requests to Dr. Young at the Intensive Care Unit, Wellington Regional Hospital, Private Bag 7902, Wellington South, New Zealand, or at paul.young@ccdhub.org.nz.

*A complete list of investigators in the ICU-ROX trial is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on October 14, 2019, at NEJM.org.

N Engl J Med 2020;382:989-98.

DOI: 10.1056/NEJMoa1903297

Copyright © 2019 Massachusetts Medical Society.



THE PROVISION OF SUPPLEMENTAL OXYGEN to patients in the intensive care unit (ICU) who require invasive mechanical ventilation often exposes them to a high fraction of inspired oxygen (F_{IO_2}) and a higher-than-normal partial pressure of arterial oxygen (P_{aO_2}).¹⁻³ Among adults undergoing mechanical ventilation, hyperoxemia has been associated with increased mortality^{4,5} and fewer days alive and free from mechanical ventilation (ventilator-free days).⁵

In a meta-analysis of randomized trials involving adults with acute illnesses, the use of oxygen without limitation according to achieved arterial oxygen saturation was associated with a higher rate of death than more restrictive approaches.⁶ In a single-center ICU trial⁷ in which approximately two thirds of the patients were receiving invasive mechanical ventilation at the time of randomization, the use of conservative oxygen therapy, a therapeutic regimen designed to minimize exposure to high levels of oxygen, was associated with a lower rate of death and a higher number of ventilator-free days than usual oxygen therapy. Since supplemental oxygen is commonly used, such findings suggest that establishing regimens for limiting oxygen use could be of value. Despite this need, there is a lack of good clinically directive data regarding strategies for oxygen administration in adults undergoing mechanical ventilation.⁷⁻⁹

Accordingly, we conducted the multicenter, binational ICU-ROX (Intensive Care Unit Randomized Trial Comparing Two Approaches to Oxygen Therapy) to test the hypothesis that conservative oxygen therapy would result in more ventilator-free days than usual oxygen therapy in adults who were expected to undergo mechanical ventilation in the ICU beyond the day after recruitment.

METHODS

TRIAL DESIGN

ICU-ROX was an investigator-initiated, parallel-group, randomized clinical trial. The management committee designed the trial, which was endorsed by the Australian and New Zealand Intensive Care Society Clinical Trials Group. The Medical Research Institute of New Zealand and the Australian and New Zealand Intensive Care Research Centre managed the trial and monitored the data quality. The trial began with a 100-patient pilot phase,¹⁰ which led to minor

changes to the protocol for the subsequent 900 patients. (These changes are described in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.) An independent data and safety monitoring committee oversaw the trial and reviewed the planned interim analyses after 100 and 500 patients had reached 28 days of follow-up. No commercial support was provided for this trial.

The protocol (available at NEJM.org), which was reported before enrollment had been completed,¹¹ was approved by the ethics committee for each participating institution. Written informed consent for enrollment or consent to continue and to use patient data was obtained from each patient or from a legal surrogate. If a patient died before providing consent, data were included if allowed by local regulations and approved by the relevant ethics committee. The members of the writing committee vouch for the accuracy and completeness of the data and analyses, and for the fidelity of the trial to the protocol.

PATIENTS

All adults (≥ 18 years of age) who were expected to receive mechanical ventilation in the ICU beyond the day after recruitment were eligible for inclusion in the trial. The exclusion criteria are provided in the Supplementary Appendix. Enrollment was restricted to patients who had received less than 2 hours of invasive mechanical ventilation or noninvasive ventilation in the ICU. Eligible patients who were not enrolled within the 2-hour time window were categorized as missed, rather than excluded, for the purposes of describing the enrollment of patients.

RANDOMIZATION AND TREATMENT

We randomly assigned patients to receive conservative oxygen therapy or usual oxygen therapy using a secure, centralized, Internet-based interface. The trial statistician generated the assignment sequence using computer-generated random numbers with variable-block randomization in a 1:1 ratio and stratification according to trial center.

In the two groups, the acceptable lower limit for oxygen saturation as measured by pulse oximetry (SpO_2) was monitored with an alarm set at a level of 90%. This alarm limit could be altered at the discretion of the treating clinician. If an

arterial blood gas showed a P_{aO_2} of less than 60 mm Hg or an arterial oxygen saturation (S_{aO_2}) lower than the acceptable Sp_{O_2} , the F_{IO_2} could be increased, regardless of the Sp_{O_2} , at the discretion of the treating clinician.

In the conservative-oxygen group, the F_{IO_2} was decreased to 0.21 and supplemental oxygen was discontinued in patients who had been extubated if the Sp_{O_2} was above the acceptable lower limit. In this group, we sought to minimize exposure to an Sp_{O_2} of 97% or higher by mandating the use of an alarm that was set to sound when the Sp_{O_2} was 97% whenever supplemental oxygen was administered in the ICU. In the usual-oxygen group, there were no specific measures limiting the F_{IO_2} or the Sp_{O_2} , and use of upper alarm limits for the Sp_{O_2} was prohibited by the protocol. In this group, the use of an F_{IO_2} of less than 0.3 during invasive ventilation was discouraged (Fig. 1).

In the two groups, the use of a high F_{IO_2} , regardless of the Sp_{O_2} , was permitted in some specific circumstances (see the Supplementary Appendix). Other aspects of care, including ventilator weaning and extubation practices, were at the discretion of the treating clinician.

Patients received the assigned oxygen-therapy strategy until discharge from the ICU or 28 days after randomization, whichever was earlier. The trial-group assignment was known to clinical staff members but was not disclosed to the patients or their families.

OUTCOME MEASURES

The primary outcome was the number of ventilator-free days from randomization to day 28.¹² We defined ventilator-free days as the total number of calendar days or portions of calendar days of unassisted breathing during the first 28 days after randomization. All the patients who had died by day 28 were considered to have had no ventilator-free days.

Key secondary outcomes were death from any cause at day 90 and day 180 after randomization, the duration of survival, the proportion of patients in paid employment at baseline who were unemployed at day 180, and cognitive function and health-related quality of life at day 180. Cause-specific mortality was also recorded.¹³

Cognitive function was assessed with the use of the Telephone Interview for Cognitive Status (TICS) questionnaire; scores on this question-

A Conservative Oxygen Therapy

Too High

Unless the F_{IO_2} is 0.21, this level should be treated as an emergency
Reduce the F_{IO_2} by 0.10 at intervals of no greater than 5 min until the Sp_{O_2} is less than 97%

Just Right

Use the lowest F_{IO_2} possible to achieve an acceptable Sp_{O_2}
If the F_{IO_2} is >0.21, it should be decreased by at least 0.05 at intervals of 30 min or less until the F_{IO_2} is 0.21 or the Sp_{O_2} falls below the target range

Too Low

The lower limit of Sp_{O_2} should be determined by the treating clinician
Use a target Sp_{O_2} of $\geq 91\%$ if no lower limit is prescribed (i.e., set the lower Sp_{O_2} alarm at 90%)
If the Sp_{O_2} falls below target range during a decrease, immediately return to the previous F_{IO_2} that achieved the target Sp_{O_2}

Sp_{O_2} 97% or more
↓
Target range
↑
 Sp_{O_2} below target range

B Usual Oxygen Therapy

Upper Limit of Sp_{O_2}

There is no protocol-defined upper limit of Sp_{O_2}
Do not use upper-limit Sp_{O_2} alarms

Target Range

Any Sp_{O_2} greater than the lower limit is acceptable
The use of an F_{IO_2} of <0.3 is discouraged

Lower Limit of Sp_{O_2}

The lower limit of Sp_{O_2} should be determined by the treating clinician
Use a target Sp_{O_2} of $\geq 91\%$ if no lower limit is prescribed (i.e., set the lower Sp_{O_2} alarm at 90%)

Upper limit of Sp_{O_2}
↓
Target range
↑
Lower limit of Sp_{O_2}

Figure 1. Treatment Administered to Patients Receiving Conservative Oxygen Therapy or Usual Oxygen Therapy.

In the two groups, the acceptable lower limit for oxygen saturation as measured by pulse oximetry (Sp_{O_2}) was monitored with an alarm set at a level of 90%. This alarm limit could be altered at the discretion of the treating clinician. If a measurement of arterial blood gas showed a partial pressure of oxygen (P_{aO_2}) of less than 60 mm Hg or an arterial oxygen saturation (S_{aO_2}) lower than the acceptable Sp_{O_2} , the fraction of inspired oxygen (F_{IO_2}) could be increased at the discretion of the treating clinician.

naire range from 0 to 41, with a higher number indicating a better outcome. Categories of cognitive function based on the TICS score were severe impairment (a score of ≤ 20), mild impairment (a score of 21 to 25), ambiguous impairment (a score of 26 to 32), and no impairment (a score of >32).¹⁴

The patients' quality of life was assessed with the use of the five-level EuroQol five dimensions (EQ-5D-5L) questionnaire; this scale evaluates mobility, personal care, usual activities, pain or discomfort, and anxiety and depression, with categorization of each of these dimensions into five levels that range from no problems to extreme problems.¹⁵ For patients with acute brain disease at randomization, we used the Extended Glasgow Outcome Scale to assess functional outcome at day 180; this scale ranges from 1 to 8, with a higher number indicating a better outcome.¹⁶ Centralized assessors who were unaware of trial-group assignments assessed cognitive status, quality of life, and function at day 180. Additional details regarding trial outcomes and subgroups are provided in the Supplementary Appendix.

STATISTICAL ANALYSIS

The statistical analysis plan was reported before the completion of enrollment.¹¹ We assumed a mean ($\pm$ SD) number of 16.4 ± 11.3 ventilator-free days in the usual-oxygen group.^{8,17} Allowing for a 15% inflation in the sample size to account for rank-based testing¹⁸ and an additional inflation of 80 patients to account for withdrawals and interim analyses, we determined that a sample size of 1000 patients would provide the trial with a power of 90% to detect an absolute between-group difference of 2.6 ventilator-free days at day 28 after randomization with a two-sided type I error rate (α) of 0.05.⁸

All the analyses were performed in the intention-to-treat population, which included all the patients who had undergone randomization with the exception of those who had withdrawn consent for the use of their data. We did not impute missing values.

For the primary analysis, we used a Wilcoxon rank-sum test with differences between medians calculated by means of quantile regression using a simplex algorithm, with the inversion method¹⁹ used to calculate 95% confidence intervals after adjustment for the trial site. We also analyzed the primary end point using quantile regression after adjustment for site, age, sex, and risk of death, as assessed by means of the Acute Physiology and Chronic Health Evaluation (APACHE) II model,²⁰ and performed an unadjusted analysis.

We report 90-day and 180-day all-cause mortality as the proportion of patients in each treat-

ment group, along with a risk difference and 95% confidence interval and with a corresponding odds ratio and 95% confidence interval. We compared survival times using log-rank tests and present these data as Kaplan–Meier curves and used a Cox proportional-hazards model to calculate hazard ratios for survival. (Odds ratios were calculated to describe the ratio of deaths in each treatment group and hazard ratios to describe mortality over time.)

For prespecified subgroups, we performed quantile regression analysis and tested for heterogeneity between subgroups in the number of ventilator-free days by fitting an interaction between treatment and subgroup. Statistical significance was indicated by a P value of 0.05 and was determined with the use of a two-sided hypothesis test. We did not correct for multiple comparisons in the evaluation of secondary or other outcomes. Thus, such results are exploratory and are reported as point estimates with 95% confidence intervals. All the analyses were performed with the use of SAS software, version 9.4 (SAS Institute). Additional details regarding the statistical analysis are provided in the Supplementary Appendix.


RESULTS

CHARACTERISTICS OF THE PATIENTS

From September 2015 through May 2018, we enrolled 1000 patients in 21 ICUs in Australia and New Zealand (Fig. 2). Consent was withdrawn by 35 patients, which left an intention-to-treat population of 965, with 484 assigned to the conservative-oxygen group and 481 to the usual-oxygen group. A comparison of the characteristics of the 100 patients who were enrolled in the pilot phase of the trial and the subsequent 900 patients who were enrolled is provided in Table S2; a comparison of the characteristics of the patients who were eligible for enrollment but did not undergo randomization and those who underwent randomization is provided in Table S3. Data regarding the primary outcome were available for the entire intention-to-treat population. The trial groups had similar characteristics at baseline (Table 1 and Tables S4 through S7).

OXYGENATION AND PROCESS OF CARE

Patients in the conservative-oxygen group spent more time receiving an FiO_2 level of 0.21 than



those in the usual-oxygen group, for a median duration of 29 hours (interquartile range, 5 to 78) and 1 hour (interquartile range, 0 to 17), respectively (absolute difference, 28 hours; 95% confidence interval [CI], 22 to 34). The conservative-

oxygen group also spent less time with an SpO_2 of 97% or higher than the usual-oxygen group, with a median duration of 27 hours (interquartile range, 11 to 63.5) and 49 hours (interquartile range, 22 to 112), respectively (absolute differ-

Table 1. Characteristics of the Patients at Baseline.*

Characteristic	Conservative Oxygen (N=484)	Usual Oxygen (N=481)
Age — yr	58.1±16.2	57.5±16.1
Male sex — no. (%)	306 (63.2)	302 (62.8)
Source of admission to ICU — no. (%)		
Emergency department	187 (38.6)	212 (44.1)
Hospital ward	107 (22.1)	82 (17.0)
Transfer from another ICU	2 (0.4)	5 (1.0)
Transfer from a non-ICU ward of another hospital	39 (8.1)	36 (7.5)
Operating room		
After elective surgery	31 (6.4)	39 (8.1)
After emergency surgery	118 (24.4)	107 (22.2)
Median hr from initiation of invasive ventilation to randomization (IQR)†	3.2 (1.6–5.4)	3.0 (1.5–5.3)
APACHE II score‡	23.6±9.3	23.3±9.4
Diagnosis subgroup		
Admitted after surgery — no. (%)	149 (30.8)	146 (30.4)
Acute brain disease — no. (%)	199 (41.1)	184 (38.3)
Pao ₂ :Fio ₂ ratio of <300 — no./total no. (%)	304/461 (65.9)	319/448 (71.2)
Suspected hypoxic–ischemic encephalopathy — no. (%)	87 (18.0)	79 (16.4)
Physiological features and support§		
Spo ₂ — %	97.1±3.1	96.7±3.7
Median Pao ₂ (IQR) — mm Hg	110 (83–177)	112 (82–167)
Pao ₂ :Fio ₂ ratio	259±146	245±138
Median PEEP (IQR) — cm of water	6 (5–10)	6 (5–10)

* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Fio₂ denotes fraction of inspired oxygen, ICU intensive care unit, IQR interquartile range, Pao₂ partial pressure of arterial oxygen (measured in millimeters of mercury), PEEP positive end-expiratory pressure, and Spo₂ oxygen saturation as measured by pulse oximetry.

† This duration includes the number of hours of ventilation before ICU admission.

‡ Scores on the APACHE (Acute Physiology and Chronic Health Evaluation) II range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death.

§ Data regarding the Fio₂ level were missing for 1 patient in the conservative-oxygen group; regarding the Pao₂ level and Pao₂:Fio₂ ratio, for 23 patients in the conservative-oxygen group and 33 in the usual-oxygen group; regarding the PEEP level, for 7 patients in the conservative-oxygen group and 11 in the usual-oxygen group; and regarding the Spo₂ level, for 3 patients in the conservative-oxygen group and 5 in the usual-oxygen group.

ence, 22 hours; 95% CI, 14 to 30). The number and percentage of hours with an Spo₂ of less than 91% and with an Spo₂ of less than 88% were similar in the two groups (Table S8).

The mean Fio₂ during the first 10 days of mechanical ventilation in the ICU and the lowest and highest Fio₂ values until day 28 are provided in Figure S1. Similarly, time-weighted mean Pao₂ values during the first 10 days of mechanical ventilation in the ICU and the lowest and highest Pao₂ values until day 28 are provided in Figure S2. For these sets of measures, all the Fio₂ and

Pao₂ values were lower in the conservative-oxygen group than in the usual-oxygen group. Additional physiological descriptors and process-of-care measures are provided in Table 2 and Table S9 and Figures S3 through S6.

PRIMARY OUTCOME

At day 28, there was no significant between-group difference in the number of ventilator-free days, with a median of 21.3 days (interquartile range, 0 to 26.3) in the conservative-oxygen group and 22.1 days (interquartile range, 0 to

Table 2. Primary Outcome and Key Secondary Outcomes and Process Measures.*

	Conservative Oxygen (N=484)	Usual Oxygen (N=481)	Between-Group Difference†	Unadjusted Odds Ratio (95% CI)
Primary outcome				
No. of ventilator-free days				
Median (IQR)	21.3 (0.0 to 26.3)	22.1 (0.0 to 26.2)	−0.3 (−2.1 to 1.6)‡	
Mean	15.5±11.8	16.0±11.5	−0.4 (−1.9 to 1.0)	
No. of days of ventilation among survivors — geometric mean (95% CI)	2.95 (2.61 to 3.33)	3.11 (2.76 to 3.51)	0.94 (0.80 to 1.11)	
Key secondary outcomes				
Death — no./total no. (%)§				
Day 90	166/479 (34.7)	156/480 (32.5)		1.10 (0.84 to 1.44)
Day 180	170/476 (35.7)	164/475 (34.5)		1.05 (0.81 to 1.37)
Process measures				
Median no. of hr from randomization to ICU discharge (IQR)	115 (58 to 231)	124 (63 to 252)	−8.4 (−27.7 to 10.9)	
Median no. of hr from randomization to hospital discharge (IQR)	298 (144 to 570)	314 (155 to 618)	−15.6 (−67.1 to 35.9)	
Median no. of vasopressor-free days (IQR)	23 (0 to 26)	23 (0 to 26)	0 (−0.5 to 0.5)	
Patients with RRT in ICU — no. (%)	94 (19.4)	108 (22.5)		0.83 (0.61 to 1.14)
Patients with tracheostomy in ICU — no. (%)	48 (9.9)	56 (11.6)		0.84 (0.56 to 1.26)

* Plus-minus values are means ±SD. The widths of the confidence intervals for secondary analyses have not been adjusted for multiple comparisons, so the intervals should not be used to infer definite differences between the groups. CI denotes confidence interval, and RRT renal-replacement therapy.

† All differences in median values were calculated with the use of quantile regression after adjustment for trial site.

‡ P=0.80 for the primary comparison.


§ Odds ratios after adjustment for age, sex, trial site, and APACHE II score are 1.06 (95% CI, 0.80 to 1.42) for death at 90 days and 1.01 (95% CI, 0.76 to 1.34) for death at 180 days.

26.2) in the usual-oxygen group (absolute difference, −0.3 days; 95% CI, −2.1 to 1.6; P=0.80) (Table 2 and Fig. S7).

SECONDARY OUTCOMES

The analyses of secondary outcomes were performed a median of 186 days (interquartile range, 181 to 197 days) after randomization. By day 180, deaths were reported for 170 of 476 patients (35.7%) in the conservative-oxygen group and 164 of 475 patients (34.5%) in the usual-oxygen group (unadjusted odds ratio, 1.05; 95% CI, 0.81 to 1.37; hazard ratio, 1.05; 95% CI, 0.85 to 1.30) (Table 2 and Fig. 3). Data regarding cause-specific mortality in the two groups are provided in Table S10.

Among the survivors, we found no evidence of a between-group difference in employment status among the patients who had been receiving pay for work at baseline, with paid employment reported in 77 of 112 patients (68.8%) in the conservative-oxygen group and in 66 of 108 (61.1%) in the usual-oxygen group (Table S11). Cognitive function was similar in the two groups, with severe cognitive impairment reported in 5 of 203 patients (2.5%) in the conservative-oxygen group and in 6 of 206 (2.9%) in the usual-oxygen group (Table S12). With respect to the mobility and personal-care components of the quality-of-life assessment, the patients in the conservative-oxygen group had a greater frequency of moderate problems and a lower frequency of severe prob-



lems than those in the usual-oxygen group. We found no evidence of differences in other domains of the quality-of-life assessment (Table S13).

SUBGROUP ANALYSIS

There was substantial heterogeneity in the effect of conservative oxygen therapy on the number of ventilator-free days in patients with suspected hypoxic–ischemic encephalopathy but not in other prespecified subgroups (Table S14). At day 28, among the patients with suspected hypoxic–ischemic encephalopathy, the median number of ventilator-free days was 21.1 (interquartile range, 0 to 26.1) in the conservative-oxygen group and none (interquartile range, 0 to 26) in the usual-oxygen group (absolute difference, 21.1 days; 95% CI, 10.4 to 28.0). In post hoc analyses of the subgroup with suspected hypoxic–ischemic encephalopathy performed at 180 days, death was reported in 37 of 86 patients (43%) in the conservative-oxygen group and in 46 of 78 (59%) in the usual-oxygen group (relative risk, 0.73; 95% CI, 0.54 to 0.99; hazard ratio, 0.67; 95% CI, 0.43 to 1.03); among these patients, an unfavorable outcome on the Extended Glasgow Outcome Scale was reported in 43 of 78 patients (55%) and 49 of 72 (68%), respectively (relative risk, 0.81; 95% CI, 0.63 to 1.05). Details regarding other post hoc analyses are provided in the Supplementary Appendix.

ADVERSE EVENTS

One patient in the conservative-oxygen group had hypoxemia with a P_{aO_2} of 33.5 mm Hg, and a second patient had a low SpO_2 but the actual value was not recorded; both of these episodes were reported as adverse events. One patient in the usual-oxygen group had an ischemic stroke that was reported as an adverse event. Details regarding adverse events are provided in the Supplementary Appendix.

DISCUSSION

In this binational, multicenter, randomized clinical trial involving adults undergoing mechanical ventilation in the ICU, there was no significant difference in the number of ventilator-free days between those who received conservative oxygen therapy (as implemented in our trial) and those who received usual oxygen therapy. We did not find evidence of significant between-group differences in 90-day mortality, 180-day mortality, or survival.

Our findings are at variance with the results of a previous single-center trial,⁷ which was stopped early after an unplanned interim analysis. In that trial, conservative oxygen therapy in the ICU was associated with a greater number of ventilator-free days and a markedly lower rate of death than usual oxygen therapy.⁷ In our trial, we prohibited the use of upper-limit SpO_2 alarms in the usual-care group but did not take specific measures to target high SpO_2 values. In the previous trial, a target SpO_2 of 97 to 100% was used in the control group, and a P_{aO_2} value of up to 150 mm Hg was allowed. In the usual-care group in our trial, the use of an FiO_2 of less than 0.3 during invasive ventilation was discouraged, whereas in the previous trial, an FiO_2 of more than 0.4 was suggested in the control group. Despite these differences, the observed exposure to oxygen as determined by the P_{aO_2} level was similar in the usual-care group in our trial and in the control group in the previous trial. In addition to these differences in approach, the enrollment in our trial was much larger and thus provided more precise and robust estimates of treatment effects.²¹

In our trial, there was a clear separation in oxygen exposure between the two groups. Patients in the conservative-oxygen group had a markedly lower number of hours with an SpO_2 of

97% or more and more hours breathing 0.21 oxygen than those in the usual-care group.

Our data are suggestive of a possible benefit of conservative oxygen therapy in patients with suspected hypoxic-ischemic encephalopathy. It is biologically plausible that conservative oxygen therapy reduces the incidence of secondary brain damage after resuscitation from cardiac arrest,²² and observational data suggest that exposure to hyperoxemia in such patients may be harmful.^{23,24} However, these findings should be considered hypothesis-generating.

Our trial has several limitations. Clinicians and research staff members were necessarily aware of trial-group assignments. However, to mitigate ascertainment bias, centralized assessors conducted the evaluations at day 180 in a blinded manner. Some outcome variables (e.g., employment status) were compared only among survivors. Because survival was a post-randomization event, such data are not randomized comparisons and may be subject to bias. Some data, particularly related to quality of life and cognition, were missing. These data may not be missing at random because patients with better (or worse) outcomes might have been harder to contact or less likely to complete interviews. Despite these caveats, since problems with mobility and personal care are common after critical illnesses,^{25,26} our finding that relatively fewer survivors in the conservative-oxygen group had severe problems in these domains is potentially important. We compared the characteristics of trial patients with those of eligible patients who did not undergo randomization. Eligible patients who were not enrolled in the trial had less severe illness and lower rates of death than those who were enrolled. Accordingly, our findings may not apply to patients with less severe illness. Since we did not include mandates regarding weaning or extubation in the protocol, changes in the FiO_2 , SpO_2 , and PaO_2 that occurred because of

treatment assignment may have affected clinicians' decisions to wean and extubate particular patients. We allowed clinicians to increase oxygen in the two groups in some specific circumstances. This factor may have exposed patients in the two groups to hyperoxemia and thereby reduced our ability to detect a between-group difference in outcomes.

In a recent systematic review and meta-analysis,⁶ investigators found that a conservative oxygen strategy was associated with a lower rate of death in acutely ill adults than a liberal oxygen strategy.⁶ In the trials that were included in this meta-analysis, many of the liberal oxygen interventions were considerably more liberal than the oxygen regimen used in our usual-care group, and relatively few of the patients were critically ill.⁶ Our trial does not preclude the possibility of benefit or harm with more liberal oxygen regimens than those used in our usual-oxygen group. Different results may also be found with different regimens for conservative oxygen therapy. Our findings decrease the probability that the use of our protocol for conservative oxygen therapy in this population would result in markedly lower mortality than the use of usual oxygen therapy. However, the confidence intervals around our mortality estimates are sufficiently wide that we cannot rule out important effects of our conservative oxygen regimen on mortality.

In conclusion, during the first 28 days in the ICU, conservative oxygen therapy, as compared with usual oxygen therapy, did not significantly affect the number of ventilator-free days among adults undergoing mechanical ventilation.

Supported by the Health Research Council of New Zealand.

Dr. Beasley reports receiving grant support from Fisher and Paykel Healthcare; and Dr. Freebairn, receiving travel support from Hamilton Medical and IMT (Bellavista). No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

APPENDIX

The affiliations of the members of the writing committee are as follows: the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland — all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) — all in Australia.

REFERENCES

1. Young PJ, Beasley RW, Capellier G, Eastwood GM, Webb SA. Oxygenation targets, monitoring in the critically ill: a point prevalence study of clinical practice in Australia and New Zealand. *Crit Care Resusc* 2015;17:202-7.
2. Helmerhorst HJ, Schultz MJ, van der Voort PH, et al. Self-reported attitudes versus actual practice of oxygen therapy by ICU physicians and nurses. *Ann Intensive Care* 2014;4:23.
3. Panwar R, Capellier G, Schmutz N, et al. Current oxygenation practice in ventilated patients — an observational cohort study. *Anaesth Intensive Care* 2013; 41:505-14.
4. Helmerhorst HJ, Roos-Blom MJ, van Westerloo DJ, de Jonge E. Association between arterial hyperoxia and outcome in subsets of critical illness: a systematic review, meta-analysis, and meta-regression of cohort studies. *Crit Care Med* 2015;43: 1508-19.
5. Helmerhorst HJ, Arts DL, Schultz MJ, et al. Metrics of arterial hyperoxia and associated outcomes in critical care. *Crit Care Med* 2017;45:187-95.
6. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *Lancet* 2018; 391:1693-705.
7. Girardis M, Busani S, Damiani E, et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the Oxygen-ICU randomized clinical trial. *JAMA* 2016;316: 1583-9.
8. Panwar R, Hardie M, Bellomo R, et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients: a pilot multicenter randomized controlled trial. *Am J Respir Crit Care Med* 2016;193:43-51.
9. Asfar P, Schortgen F, Boissramé-Helms J, et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERSS2S): a two-by-two factorial, multicentre, randomised, clinical trial. *Lancet Respir Med* 2017;5:180-90.
10. Young PJ, Mackle DM, Bailey MJ, et al. Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX): results of the pilot phase. *Crit Care Resusc* 2017;19:344-54.
11. Mackle DM, Bailey MJ, Beasley RW, et al. Protocol summary and statistical analysis plan for the intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX). *Crit Care Resusc* 2018;20:22-32.
12. Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. *Crit Care Med* 2002;30:1772-7.
13. Ridgeon E, Bellomo R, Myburgh J, et al. Validation of a classification system for causes of death in critical care: an assessment of inter-rater reliability. *Crit Care Resusc* 2016;18:50-4.
14. Davydow DS, Zatzick D, Hough CL, Katon WJ. In-hospital acute stress symptoms are associated with impairment in cognition 1 year after intensive care unit admission. *Ann Am Thorac Soc* 2013;10: 450-7.
15. Badia X, Diaz-Prieto A, Gorris MT, et al. Using the EuroQol-5D to measure changes in quality of life 12 months after discharge from an intensive care unit. *Intensive Care Med* 2001;27:1901-7.
16. Weir J, Steyerberg EW, Butcher I, et al. Does the extended Glasgow Outcome Scale add value to the conventional Glasgow Outcome Scale? *J Neurotrauma* 2012;29:53-8.
17. Suzuki S, Eastwood GM, Glassford NJ, et al. Conservative oxygen therapy in mechanically ventilated patients: a pilot before-and-after trial. *Crit Care Med* 2014; 42:1414-22.
18. Lehmann EL. Nonparametrics: statistical methods based on rank. Rev. ed. New York: Springer, 2006.
19. Koenker RW, D'Orey V. Computing regression quantiles. *Appl Stat* 1993;43: 410-4.
20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med* 1985;13:818-29.
21. Ferguson ND. Oxygen in the ICU: too much of a good thing? *JAMA* 2016;316: 1553-4.
22. Pilcher J, Weatherall M, Shirlcliffe P, Bellomo R, Young P, Beasley R. The effect of hyperoxia following cardiac arrest — a systematic review and meta-analysis of animal trials. *Resuscitation* 2012;83:417-22.
23. Roberts BW, Kilgannon JH, Hunter BR, et al. Association between early hyperoxia exposure after resuscitation from cardiac arrest and neurological disability: prospective multicenter protocol-directed cohort study. *Circulation* 2018;137:2114-24.
24. Kilgannon JH, Jones AE, Shapiro NI, et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. *JAMA* 2010;303:2165-71.
25. Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364:1293-304.
26. Hodgson CL, Bailey M, Bellomo R, et al. A binational multicenter pilot feasibility randomized controlled trial of early goal-directed mobilization in the ICU. *Crit Care Med* 2016;44:1145-52.

Copyright © 2019 Massachusetts Medical Society.